Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides.
about
Enhanced immunogenicity of a functional enzyme by T cell epitope modificationA human dendritic cell-based method to identify CD4+ T-cell epitopes in potential protein allergensLung cancer vaccinesT cells in atherosclerosisStructure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial VirusAbnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins.Elicitation of structure-specific antibodies by epitope scaffoldsDesign and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial VirusInsertion of foreign T cell epitopes in human tumor necrosis factor alpha with minimal effect on protein structure and biological activity.Synthetic Long Peptide Influenza Vaccine Containing Conserved T and B Cell Epitopes Reduces Viral Load in Lungs of Mice and Ferrets.Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy.Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell responseReducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy.Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan.A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice.A versatile selection system for folding competent proteins using genetic complementation in a eukaryotic host.Five HLA-DP molecules frequently expressed in the worldwide human population share a common HLA supertypic binding specificity.The MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates.Engineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens.Construction of an enantiopure bivalent nicotine vaccine using synthetic peptides.Synthetic peptide vaccines effective in preventing virus infection.Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes.Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic miceEnhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun.RETRACTED: B7-DC cross-linking restores antigen uptake and augments antigen-presenting cell function by matured dendritic cells.PeptX: using genetic algorithms to optimize peptides for MHC binding.Convergent synthetic methodology for the construction of self-adjuvanting lipopeptide vaccines using a novel carbohydrate scaffold.Strategies to use immune modulators in therapeutic vaccines against cancerProgress on new vaccine strategies for the immunotherapy and prevention of cancer.A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles.Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activationVaccination with lipid core peptides fails to induce epitope-specific T cell responses but confers non-specific protective immunity in a malaria modelA mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 2-model applications.Towards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201Trial Watch: Peptide-based anticancer vaccines.Increased pulmonary tumor necrosis factor alpha, interleukin-6 (IL-6), and IL-17A responses compensate for decreased gamma interferon production in anti-IL-12 autovaccine-treated, Mycobacterium bovis BCG-vaccinated mice.Titrating T-cell epitopes within self-assembled vaccines optimizes CD4+ helper T cell and antibody outputsPitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.
P2860
Q24802822-6052C5A9-B88F-427D-976D-F78CFB84A90BQ24813625-6395C889-E99B-4A29-ACA3-6354B0B80499Q27014375-8A631ED6-5A4D-4655-A15F-19EBC539B4A0Q27025697-367D7FA4-87DD-46FE-BB1A-01F0640286E4Q27333522-2AC54CE0-1BFA-492E-99F2-5FE1CB8E49EEQ27472875-7C1CC339-D8BB-40F8-9B5D-164E944A2FA9Q27664711-766A907C-3B34-4309-A0F7-D307D90457AEQ27667750-AC7EC375-34BA-4F57-9CB6-A7CCD108BF03Q30341702-6396A0EA-F10F-4606-B7E8-2F5DF26D8574Q30375348-F10C1CC1-D24D-4E28-89AE-CE40F8047C08Q30584571-2AD153A9-7F9D-43FE-B64B-365B5A79A0F2Q31121276-5FF4A507-2368-4B0B-843D-01246237E7DBQ31155155-965A8600-8D9F-47D5-8A78-77A5419A6145Q33332164-610A9913-F81F-423A-8348-B25C03A5C0C5Q33349439-19C98686-CC9E-4134-A1AB-DFAF6DA06AABQ33504189-64533DB7-3B89-415E-BCF2-C3EBB3FE5C62Q33524859-309C864D-70BA-4F9F-AFAD-117661D477B7Q33530024-D3CDCBE9-5A27-4222-8F4B-66E568E24E75Q33560798-556F89F9-4CD3-4CF0-BB33-D8787ED39CF4Q33698112-FB0A661C-A528-4411-9185-00BDEE2158FAQ33751968-FB568859-B511-4CAD-83AA-D333DE5C0530Q33786753-0FFF4E38-94FE-4942-B2F7-B9A91D351CBBQ33812812-8F3FE628-F5B7-4703-94AC-48AD3EB412C7Q33839448-A79B3592-D7BE-4083-8C62-5728182E853DQ33855226-C78273A4-F9F9-4327-BCE3-7E413EC1719CQ33860104-F48C5BBD-5AA1-4E9C-B3DC-1C92F143C279Q33913924-21C214C5-87EE-44CA-9074-1215DF61CB7FQ33934654-3094E019-3D56-48F3-81D8-436718780F4FQ34083111-DE999CF4-1ACB-4BF0-9FD6-7EA0ECA52CE7Q34275601-68E1453B-0719-440D-99EC-05E71251824EQ34328457-560E732C-6B46-43CD-BC31-3B5275DB1E27Q34365057-FCD4C4D6-01CB-4CE3-9BEB-F18F01AF442AQ34397856-4541EC0E-30DA-4F69-B96E-3D50FDA26E9EQ34398787-00B9D13B-3F50-42A6-9275-C956CE266665Q34413009-4EB5DD4C-E26E-4044-A11A-054B1C197552Q34458916-0999F411-50FB-4E35-AA2F-ECE0C90698ADQ34483345-F4198A94-5EA9-4DC7-9194-871107D3D5B2Q34484151-4047A8B3-B9FA-4B49-BD9D-F2C95E64C439Q34490296-EFDC4D07-46B3-4AE7-B65E-CE88AE850D61Q34508125-38CE1A81-4FE0-4BF3-A428-1DB3A13D0EF5
P2860
Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
Development of high potency un ...... affinity DR-blocking peptides.
@en
Development of high potency un ...... affinity DR-blocking peptides.
@nl
type
label
Development of high potency un ...... affinity DR-blocking peptides.
@en
Development of high potency un ...... affinity DR-blocking peptides.
@nl
prefLabel
Development of high potency un ...... affinity DR-blocking peptides.
@en
Development of high potency un ...... affinity DR-blocking peptides.
@nl
P2093
P1433
P1476
Development of high potency un ...... affinity DR-blocking peptides
@en
P2093
J Alexander
S Southwood
P304
P356
10.1016/S1074-7613(94)80017-0
P407
P577
1994-12-01T00:00:00Z